Perspective Therapeutics, Inc. (CATX)

1,7000 +0,0200 (+1,19%) Alla chiusura: 04:00PM EDT

Perspective Therapeutics, Inc.

2401 Elliott Avenue
Suite 320
Seattle, WA 98121
United States
206-676-0900
https://www.perspectivetherapeutics.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 116

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Johan M. Spoor	CEO & Director	855,78k	N/D	1972
Mr. Jonathan R. Hunt	CFO & Co-Principal Financial Officer	944,35k	N/D	1967
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer	633,14k	N/D	1966
Mr. Shane Cobb	Executive Vice President of Operations	N/D	N/D	N/D
Mr. Mark J. Austin CPA	VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary	N/D	N/D	1987
Dr. Michael K. Schultz Ph.D.	Chief Science Officer	N/D	N/D	N/D
Mr. Andrew Bright	Executive Vice President of Brachytherapy	N/D	N/D	N/D
Mr. Amos Hedt BA, PGradDip	Chief Business Strategy Officer	N/D	N/D	N/D
Dr. Frances L. Johnson M.D.	Chief Innovation Officer	N/D	N/D	N/D
Mr. David Hauser Ph.D.	Senior Vice President of Clinical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Governance aziendale

L'ISS Governance QualityScore di Perspective Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.